Sponsor or institution
Clinical trials and research at Women's Cancer Study Group GmbH
As of November 12, 2026, Find a Trial lists 5 clinical trials run by Women's Cancer Study Group GmbH that are recruiting, at sites in 3 countries (most in Germany (5), Belgium (1), Portugal (1)). By phase: Phase 3 (3), Phase 2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 3Countries
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Capivasertib plus endocrine therapy for HR+/HER2- advanced breast cancer after progression on endocrine treatment | Phase 3 | Anderlecht and 15 other locations | Recruiting | Dec 15, 2025 |
| Marker-guided adjuvant elacestrant versus standard endocrine therapy for intermediate-to-high-risk HR+/HER2- early breast cancer | Phase 3 | Mannheim, Baden-Wurttemberg and 32 other locations | Recruiting | Nov 21, 2025 |
| Comparing two treatments for low-risk triple-negative breast cancer | Phase 3 | Baden-Baden, Baden-Wurttemberg and 42 other locations | Recruiting | Oct 13, 2023 |
| Registry for Premenopausal Women with Breast Cancer Treated with Ovarian Function Suppression | — | Baden-Baden, Baden-Wurttemberg and 70 other locations | Recruiting | Mar 31, 2023 |
| Neoadjuvant therapy for HER2-positive early breast cancer | Phase 2 | Baden-Baden, Baden-Wurttemberg and 43 other locations | Recruiting | Jan 30, 2023 |
All recruiting trials (5)
-
Capivasertib plus endocrine therapy for HR+/HER2- advanced breast cancer after progression on endocrine treatment
This trial will test whether adding capivasertib to standard endocrine therapy helps adults with HR+/HER2- advanced or metastatic breast cancer who progressed on prior endocrine treatment stay on treatment longer and maintain quality of life.
-
Marker-guided adjuvant elacestrant versus standard endocrine therapy for intermediate-to-high-risk HR+/HER2- early breast cancer
This trial will test whether giving elacestrant (with or without a CDK4/6 inhibitor) as initial adjuvant therapy for adults with gene-test or clinical intermediate-to-high-risk HR+/HER2- early breast cancer reduces recurrence compared with standard endocrine treatment.
-
Comparing two treatments for low-risk triple-negative breast cancer
This study is testing whether adding pembrolizumab to sacituzumab govitecan can help people with low-risk triple-negative breast cancer do better after their initial treatment.
-
Registry for Premenopausal Women with Breast Cancer Treated with Ovarian Function Suppression
This study is collecting information from premenopausal women with early breast cancer to see how ovarian function suppression affects their treatment results, medication adherence, and quality of life over time.
-
Neoadjuvant therapy for HER2-positive early breast cancer
This study is testing if a new drug called trastuzumab-deruxtecan can work better than standard chemotherapy for people with early HER2-positive breast cancer to see if it helps them respond better to treatment.
Quick answers
How many clinical trials run by Women's Cancer Study Group GmbH are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 3 countries. The most sites are in Germany (5 trials), Belgium (1 trial), Portugal (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 3: 3, Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.